Curing Obesity by Dave Lashmet with Stansberry Venture Technology
by chiefalbob | August 26, 2020 9:24 pm
It’s the stock of a tiny, little-known pharmaceutical company, trading for less than $50 a share. This company controls a potential cure for the obesity[1] epidemic.
Dave has done the research, dating back four years. He’s one of a handful of people outside this company’s headquarters who are aware of what’s going on and the nuances of this drug’s development, approval process, and why the company has been so secretive about it.
This drug turns down our natural “hunger switch.” It essentially gives you a higher metabolism. It’s a potentially world-changing drug, and it’s completely under the radar… but won’t be for much longer.
- obesity: https://www.stockgumshoe.com/tag/obesity/
Source URL: https://www.stockgumshoe.com/2020/08/microblog-curing-obesity-by-dave-lashmet-with-stansberry-venture-technology/
Maybe ENTA (Enanta) Around $50 and doing something in the obesity field if I understand correctly.
https://www.enanta.com/research/nash/default.aspx
I don’t think ENTA is it. Their research is in Fatty Liver disease not cause by alcohol. The other research refers to respiratory viruses and hepatitus B. I don’t see anything where they are working on obesity.
Indeed. I was wrong. Travis has already solved it!
Here you go: https://www.stockgumshoe.com/reviews/stansberry-venture/whats-the-20x-weight-loss-drug-looking-into-lashmets-new-teaser-pitch-for-stansberry-venture-technology/
I say it is Rhythm Pharmaceuticals RYTM. I have seen his video at Dailywealth.com.
Go to to Biospace.com and enter Rhythm.
Go to Seekingalpha.com and enter the symbol. On the page showing the price chart look for
“Investor Presentation Slide Show.”
I think the drug is setmelanotide.